Responses
Immune cell therapies and immune cell engineering
Original research
Clinical efficacy of T-cell therapy after short-term BRAF-inhibitor priming in patients with checkpoint inhibitor-resistant metastatic melanoma
Compose a Response to This Article
Other responses
No responses have been published for this article.
